Apogee Therapeutics, Inc.

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell APGE and other ETFs, options, and stocks.

About APGE

Apogee Therapeutics, Inc. operates as a biotechnology company. It offers treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications. 

CEO
Michael Henderson
CEOMichael Henderson
Employees
196
Employees196
Headquarters
Waltham, Massachusetts
HeadquartersWaltham, Massachusetts
Founded
2022
Founded2022
Employees
196
Employees196

APGE Key Statistics

Market cap
5.73B
Market cap5.73B
Price-Earnings ratio
-19.09
Price-Earnings ratio-19.09
Dividend yield
Dividend yield
Average volume
1.05M
Average volume1.05M
High today
High today
Low today
Low today
Open price
$78.94
Open price$78.94
Volume
0.00
Volume0.00
52 Week high
$84.56
52 Week high$84.56
52 Week low
$26.20
52 Week low$26.20

Stock Snapshot

As of today, Apogee Therapeutics, Inc.(APGE) shares are valued at $82.43. The company's market cap stands at 5.73B, with a P/E ratio of -19.09.

On 2026-01-15, Apogee Therapeutics, Inc.(APGE) shares started trading at $78.94, with intraday highs of — and lows of —.

Trading activity shows a volume of 0, compared to an average daily volume of 1.05M.

Over the past 52 weeks, Apogee Therapeutics, Inc.(APGE) stock has traded between a high of $84.56 and a low of $26.20.

Over the past 52 weeks, Apogee Therapeutics, Inc.(APGE) stock has traded between a high of $84.56 and a low of $26.20.

Analyst ratings

94%

of 16 ratings
Buy
93.8%
Hold
6.3%
Sell
0%

People also own

Based on the portfolios of people who own APGE. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the .